# EDGAR Filing Document

**Accession Number:** 0001814114
**File Stem:** 0001104659-26-011522
**Filing Date:** 2026-2
**Character Count:** 29248
**Document Hash:** 0fd5d47a390c12378d9416acb49c978b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-011522.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0001104659-26-011522

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20260206

**DATE AS OF CHANGE**: 20260206

**EFFECTIVENESS DATE**: 20260206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Orchestra BioMed Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001814114
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293267
- **FILM NUMBER:** 26607831

**BUSINESS ADDRESS:**
- **STREET 1:** 150 UNION SQUARE DRIVE
- **CITY:** NEW HOPE
- **STATE:** PA
- **ZIP:** 18938
- **BUSINESS PHONE:** 646-343-9298

**MAIL ADDRESS:**
- **STREET 1:** 150 UNION SQUARE DRIVE
- **CITY:** NEW HOPE
- **STATE:** PA
- **ZIP:** 18938

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Health Sciences Acquisitions Corp 2
- **DATE OF NAME CHANGE:** 20200603

**As filed with the Securities and Exchange Commission on February 6, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**ORCHESTRA BIOMED HOLDINGS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **92-2038755** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**150 Union Square Drive**

**New Hope, Pennsylvania 18928**

**(Address of Principal Executive Offices) (Zip Code)**

**Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan**

**(Full titles of the plans)**

**David P. Hochman**

**Chief Executive Officer**

**150 Union Square Drive**

**New Hope, PA 18928**

**(215) 862-5797**

**(Name, address and telephone number, including area code, of agent for service)**

***Copies to:***

**Yariv Katz, Esq.**

**Keith Pisani, Esq.**

**Paul Hastings LLP**

**200 Park Avenue**

**New York, NY 10016**

**(212) 318-6000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ¨ | Accelerated filer | ¨ |
| Non-accelerated filer | x | Smaller reporting company | x |
|  |  | Emerging growth company | ¨ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE; INCORPORATION BY REFERENCE OF CONTENTS OF<br> REGISTRATION STATEMENTS ON FORM S-8**

Pursuant to General Instruction E of Form S-8, Orchestra BioMed Holdings, Inc. (the "Registrant" or the "Company") is filing this Registration Statement with the Securities and Exchange Commission (the "SEC") to register 2,737,582 additional shares of common stock, par value $0.0001 per share ("Common Stock"), of the Registrant reserved for issuance under the Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan (the "2023 Plan") resulting from an automatic annual increase as of January 1, 2026. This Registration Statement hereby incorporates by reference the contents of the Registrant's previous Registration Statements on Form S-8 filed with the SEC on [April 3, 2023 (File No. 333-271092)](https://www.sec.gov/Archives/edgar/data/1814114/000121390023026395/ea176305-s8_orchestra.htm), [March 27, 2024 (File No. 333-278285)](https://www.sec.gov/Archives/edgar/data/1814114/000110465924039763/tm2324184d7_s8.htm) and [February 19, 2025 (File No. 333-285058)](https://www.sec.gov/Archives/edgar/data/1814114/000110465925015184/tm256935d1_s8.htm).

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF DOCUMENTS BY REFERENCE.** |

---

The following documents filed by the Registrant with the SEC are hereby incorporated by reference into this Registration Statement:

(a) [The Registrant's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025;](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000155837025004161/obio-20241231x10k.htm)

(b) The Registrant's Quarterly Reports on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on [May 12, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000155837025007373/obio-20250331x10q.htm) , for the quarter ended June 30, 2025, filed with the SEC on [August 12, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000155837025011148/obio-20250630x10q.htm) , and for the quarter ended September 30, 2025, filed with the SEC on [November 10, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000110465925109128/obio-20250930x10q.htm) ;

(c) The Registrant's Current Reports on Form 8-K, filed with SEC on [February 5, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000110465925009393/tm255461d1_8k.htm) (excluding the information furnished under Item 7.01), [February 25, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000110465925016950/tm257515d1_8k.htm) , [April 29, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000110465925040763/tm2513456d1_8k.htm) (excluding the information furnished under Item 7.01), [June 24, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000110465925062105/tm2518830d1_8k.htm) , [July 31, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000110465925072678/tm2522158d1_8k.htm) (excluding the information furnished under Item 7.01), [August 4, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000110465925073641/tm2522158d2_8k.htm) (excluding the information furnished under Item 7.01), [October 28, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000110465925102862/tm2529597d1_8k.htm) (excluding the information furnished under Item 7.01) and [January 12, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1814114/000110465926002752/tm262832d1_8k.htm) ; and

(d) The description of the Registrant's Common Stock contained in [Exhibit 4.18](https://www.sec.gov/Archives/edgar/data/1814114/000155837025004161/obio-20241231xex4d18.htm) to the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025, including any amendment or reports filed for the purpose of updating such description.

All other reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of the filing of such reports and documents, except as to any portion of any future current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.

For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

You may contact the Registrant in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits to such documents unless such exhibits are specifically incorporated by reference into the information incorporated into this Registration Statement). Requests for such information should be directed to:

Orchestra BioMed Holdings, Inc.

150 Union Square Drive

New Hope, PA 18938

Attn: Chief Executive Officer

**ITEM 8. EXHIBITS.**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1814114/000121390023006448/ea172444ex3-1_orchestra.htm) | [Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on January 31, 2023).](https://www.sec.gov/Archives/edgar/data/1814114/000121390023006448/ea172444ex3-1_orchestra.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1814114/000110465925109128/obio-20250930xex3d2.htm) | [Certificate of Designation of Series A Convertible Preferred Stock of the Registrant (incorporated by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q filed by the Registrant on November 10, 2025)](https://www.sec.gov/Archives/edgar/data/1814114/000110465925109128/obio-20250930xex3d2.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1814114/000155837024011899/obio-20240630xex3d2.htm) | [Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q filed by the Registrant on August 12, 2024).](https://www.sec.gov/Archives/edgar/data/1814114/000155837024011899/obio-20240630xex3d2.htm) |
| [5.1\*](tm265026d1_ex5-1.htm) | [Opinion of Paul Hastings LLP.](tm265026d1_ex5-1.htm) |
| [23.1\*](tm265026d1_ex23-1.htm) | [Consent of Ernst & Young LLP, independent registered public accounting firm of the Registrant.](tm265026d1_ex23-1.htm) |
| [23.2\*](tm265026d1_ex5-1.htm) | [Consent of Paul Hastings LLP (included in Exhibit 5.1).](tm265026d1_ex5-1.htm) |
| [24.1\*](#a_001) | [Power of Attorney is contained on the signature page.](#a_001) |
| [99.1#](https://www.sec.gov/Archives/edgar/data/1814114/000121390023006448/ea172444ex10-7_orchestra.htm) | [Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed by the Registrant on January 31, 2023).](https://www.sec.gov/Archives/edgar/data/1814114/000121390023006448/ea172444ex10-7_orchestra.htm) |
| [99.2#](https://www.sec.gov/Archives/edgar/data/1814114/000121390023006448/ea172444ex10-8_orchestra.htm) | [Form of Stock Option Grant Notice and Stock Option Agreement under the Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed by the Registrant on January 31, 2023).](https://www.sec.gov/Archives/edgar/data/1814114/000121390023006448/ea172444ex10-8_orchestra.htm) |
| [99.3#](https://www.sec.gov/Archives/edgar/data/1814114/000121390023006448/ea172444ex10-9_orchestra.htm) | [Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Current Report on Form 8-K filed by the Registrant on January 31, 2023).](https://www.sec.gov/Archives/edgar/data/1814114/000121390023006448/ea172444ex10-9_orchestra.htm) |
| [107\*](tm265026d1_ex-filingfees.htm) | [Filing Fee Table](tm265026d1_ex-filingfees.htm) |

---

\* Filed herewith. <br> # Indicates a management contract or compensatory plan.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in city of New York, State of New York, on February 6, 2026.

---

| | |
|:---|:---|
| **ORCHESTRA BIOMED HOLDINGS, INC.** | **ORCHESTRA BIOMED HOLDINGS, INC.** |
| By: | /s/ David P. Hochman |
| Name: | David P. Hochman |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY**

**KNOW ALL PERSONS BY THESE PRESENTS,** that each person whose signature appears below constitutes and appoints David P. Hochman and Andrew L. Taylor, and each or any one of them, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **SIGNATURE** | **TITLE** | **DATE** |
| /s/ David P. Hochman | Chief Executive Officer, Chairperson and Director | February 6, 2026 |
| David P. Hochman | (*Principal Executive Officer*) |  |
| /s/ Andrew L. Taylor | Chief Financial Officer | February 6, 2026 |
| Andrew L. Taylor | (*Principal Financial Officer*) |  |
| /s/ Joshua Aiello | Corporate Controller | February 6, 2026 |
| Joshua Aiello | (*Principal Accounting Officer*) |  |
| /s/ Jason Aryeh | Director | February 6, 2026 |
| Jason Aryeh |  |  |
| /s/ Chris Cleary | Director | February 6, 2026 |
| Chris Cleary |  |  |
| /s/ Pamela A. Connealy | Director | February 6, 2026 |
| Pamela A. Connealy |  |  |
| /s/ Eric S. Fain, M.D. | Director | February 6, 2026 |
| Eric S. Fain, M.D. |  |  |
| /s/ David Pacitti | Director | February 6, 2026 |
| David Pacitti |  |  |
| /s/ John Mack | Director | February 6, 2026 |
| John Mack |  |  |
| /s/ Darren R. Sherman | Chief Operating Officer and Director | February 6, 2026 |
| Darren R. Sherman |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](tm265026d1_ex5-1img001.jpg)

February 6, 2026

Orchestra BioMed Holdings, Inc.<br> 150 Union Square Drive<br> New Hope, PA 18938

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to Orchestra BioMed Holdings, Inc., a Delaware corporation (the "***Company***"), in connection with the preparation of the registration statement on Form S-8 to be filed by the Company with the U.S. Securities and Exchange Commission (the "***Commission***") on the date hereof (the "***Registration Statement***") to effect registration under the Securities Act of 1933, as amended (the "***Securities Act***"), of 2,737,582 shares (the "***Shares***") of the Company's common stock, $0.0001 par value per share ("***Common Stock***"), reserved for awards available for future issuance under the Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan (the "***2023 Plan***").

As such counsel and for purposes of our opinion set forth below, we have examined and relied upon originals or copies, certified or otherwise identified to our satisfaction, of such documents, resolutions, certificates and instruments of the Company and corporate records furnished to us by the Company, and have reviewed certificates of public officials, statutes, records and such other instruments and documents as we have deemed necessary or appropriate as a basis for the opinion set forth below, including, without limitation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the Certificate of Incorporation of the Company (the "  ***Certificate of Incorporation*** "), as certified as of
February 6, 2026 by the Office of the Secretary of State of the State of Delaware;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the Amended and Restated Bylaws of the Company as presently in effect, as certified by an officer of the Company on February 6,
2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) the 2023 Plan and the forms of award agreements related thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) a certificate, dated as of February 6, 2026, from the Office of the Secretary of State of the State of Delaware, certifying as
to the existence and good standing of the Company in the State of Delaware (the "  ***Good Standing Certificate*** ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) the resolutions adopted by the board of directors of the Health Sciences Acquisitions Corporation 2 ("  ***HSAC2*** "),
the resolutions adopted by the board of directors of the Company and the resolutions adopted by the Compensation Committee of the Company
regarding the 2023 Plan, and other matters related thereto, as certified by an officer of the Company on February 6, 2026;

![](tm265026d1_ex5-1img002.jpg)

![](tm265026d1_ex5-1img003.jpg)

Orchestra BioMed Holdings, Inc.

February 6, 2026

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) the resolutions adopted by the shareholders of HSAC2 regarding the 2023 Plan, and other matters related thereto, as certified by an
officer of the Company on February 6, 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) the agreement and plan of merger, dated as of July 4, 2022, by and among HSAC2, HSAC Olympus Merger Sub, Inc., and Orchestra
BioMed, Inc., as amended.

In addition to the foregoing, we have made such investigations of law as we have deemed necessary or appropriate as a basis for the opinion set forth in this opinion letter.

In such examination and in rendering the opinion expressed below, we have assumed, without independent investigation or verification: (i) the genuineness of all signatures on all agreements, instruments, corporate records, certificates and other documents submitted to us; (ii) the authenticity and completeness of all agreements, instruments, corporate records, certificates and other documents submitted to us as originals; (iii) that all agreements, instruments, corporate records, certificates and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or other copies conform to originals thereof, and that such originals are authentic and complete; (iv) the legal capacity, competency and authority of all individuals executing all agreements, instruments, corporate records, certificates and other documents; (v) the due authorization, execution and delivery of all agreements, instruments, corporate records, certificates and other documents by all parties thereto (other than the Company); (vi) that no documents submitted to us have been amended or terminated orally or in writing except as has been disclosed to us in writing; (vii) that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the Company and other persons on which we have relied for the purposes of this opinion letter are true and correct on and as of the date hereof; (viii) that there has not been any change in the good standing status of the Company from that reported in the Good Standing Certificate; and (ix) that each of the officers and directors of the Company has properly exercised his or her fiduciary duties. As to all questions of fact material to this opinion letter, and as to the materiality of any fact or other matter referred to herein, we have relied (without independent investigation or verification) upon representations and certificates or comparable documents of officers and representatives of the Company. We have also assumed that the individual issuances, grants, awards or grants of purchase rights under the 2023 Plan will be duly authorized by all necessary corporate action of the Company and duly issued, granted or awarded and exercised in accordance with the requirements of law, the 2023 Plan and the agreements, forms of instrument, awards and grants duly adopted thereunder. We have also assumed that upon the issuance of any Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Certificate of Incorporation.

Based upon the foregoing, and in reliance thereon, and subject to the assumptions, limitations, qualifications and exceptions set forth herein, we are of the opinion that the Shares are duly authorized and, when issued and sold in accordance with the Registration Statement, the related prospectus, the 2023 Plan and the applicable award agreements or forms of instrument evidencing purchase rights thereunder (including the receipt by the Company of the full consideration therefor), will be validly issued, fully paid and nonassessable.

Without limiting any of the other assumptions, limitations, qualifications and exceptions stated elsewhere herein, we express no opinion with regard to the applicability or effect of the laws of any jurisdiction other than the General Corporation Law of the State of Delaware, as in effect on the date of this opinion letter.

![](tm265026d1_ex5-1img003.jpg)

Orchestra BioMed Holdings, Inc.

February 6, 2026

This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly stated herein from any matter addressed in this opinion letter.

This opinion letter is rendered solely in connection with the preparation and filing of the Registration Statement. This opinion letter is rendered as of the date hereof, and we assume no obligation to advise you or any other person with regard to any change after the date hereof in the circumstances or the law that may bear on the matters set forth herein even if the change may affect the legal analysis or a legal conclusion or other matters in this opinion letter.

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules or regulations of the Commission thereunder.

Very truly yours,

/s/ Paul Hastings LLP

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan of Orchestra BioMed Holdings, Inc. of our report dated March 31, 2025, with respect to the consolidated financial statements of Orchestra BioMed Holdings, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Philadelphia, Pennsylvania

February 6, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Orchestra BioMed Holdings, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.0001 per share | Other | 2737582 | $3.87 | $10594442.34 | 0.0001381 | $1463.09 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $10594442.34  |  | $1463.09  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $1463.09  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock that become issuable under the 2023 Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock. The "Amount Registered" represents the additional shares of Common Stock reserved for issuance under the 2023 Plan resulting from an automatic annual increase as of January 1, 2026. The "Proposed Maximum Offering Price" is estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) of the Securities Act, and is calculated based on $3.87 per share, the average of the high and low prices of the Common Stock, as reported on the Nasdaq Global Market on February 2, 2026, which is a date within five business days prior to the date of filing the Registration Statement.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---